Interpace Diagnostics Group (NASDAQ:IDXG) released its quarterly earnings results on Thursday. The business services provider reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.24) by ($1.08), Fidelity Earnings reports. The business had revenue of $9.20 million for the quarter, compared to the consensus estimate of $8.95 million. Interpace Diagnostics Group had a negative net margin of 110.80% and a negative return on equity of 119.88%. Interpace Diagnostics Group updated its Q2 2020
After-Hours guidance to EPS.
Interpace Diagnostics Group stock opened at $4.73 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.95 and a current ratio of 0.95. The stock’s 50 day moving average is $5.12 and its 200 day moving average is $5.16. Interpace Diagnostics Group has a twelve month low of $3.81 and a twelve month high of $11.00.
IDXG has been the subject of a number of recent analyst reports. ValuEngine raised Interpace Diagnostics Group from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, June 17th. Alliance Global Partners lowered their price target on Interpace Diagnostics Group from $21.00 to $9.25 and set a “buy” rating for the company in a research report on Thursday, April 23rd. Maxim Group reissued a “buy” rating and issued a $12.00 target price on shares of Interpace Diagnostics Group in a research report on Friday, April 24th. HC Wainwright reissued a “buy” rating and issued a $11.00 target price (down previously from $12.00) on shares of Interpace Diagnostics Group in a research report on Friday. Finally, Janney Montgomery Scott assumed coverage on Interpace Diagnostics Group in a research report on Wednesday, April 15th. They issued a “buy” rating for the company. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Interpace Diagnostics Group has an average rating of “Buy” and a consensus target price of $8.81.
Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules.
Featured Story: Cost of Capital
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.